Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
VistaGen Therapeutics, Inc. (VTGN)
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vistagen.com
Company Research
Source: GlobeNewswire
NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Vistagen Therapeutics caused the company to misrepresent or fail to disclose the risk of failure inherent in public speaking challenge-based Social Anxiety Disorder clinical trials. Specifically, that from its own Phase 2 experience and published clinical research that public speaking challenge endpoints often exhibit elevated placebo responses, site variability and measurement noise, yet they continued to tout modifications made to the Phase 3 trial and presenting PALISADE-3 as likely to succeed. If you currently own VTGN and purchased prior to April 01, 2024 please contact Justin Kuehn, Esq. by email at justin@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does
Show less
Read more
Impact Snapshot
Event Time:
VTGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTGN alerts
High impacting VistaGen Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VTGN
News
- Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Reach OutACCESS Newswire
- Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock DropPR Newswire
- Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Reach OutACCESS Newswire
- Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to ConnectACCESS Newswire
- Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to MenopauseBusiness Wire
VTGN
Earnings
- 2/12/26 - Beat
VTGN
Sec Filings
- 4/28/26 - Form 8-K
- 4/13/26 - Form 8-K
- 4/9/26 - Form 4
- VTGN's page on the SEC website